Preliminary data show that ibrutinib and PI3Kδ inhibitor idelalisib synergistically inhibit BCR-controlled adhesion, resulting in increased mobilization of CLL cells from niches75. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.